Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.
The transaction involves a total consideration of up to $30m to Repare and directly influences the company’s cash status and upcoming shareholder arrangements.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the terms, Gilead will pay Repare $25m upfront, subject to customary holdbacks and adjustments, and up to an additional $5m upon completion of certain technology transfer activities.
On 14 November 2025, Repare announced a definitive arrangement agreement with XenoTherapeutics and Xeno Acquisition. Under this agreement, Xeno agreed to purchase all of Repare’s issued and outstanding common shares.
The amount of cash each shareholder will receive per share will be based on Repare’s closing cash balance, after subtracting transaction-related expenses and outstanding liabilities.
The upfront payment from the Polθ ATPase inhibitor acquisition has increased Repare’s cash reserves, thereby raising the estimate for shareholder payments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBased on the revised cash balance, Repare estimates shareholders will receive about $2.20 per common share upon closing the arrangement transaction.
Repare Therapeutics president, CEO and chief financial officer Steve Forte said: “We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor. This marks the third and most significant portfolio transaction for Repare this year.”
RP-3467 is a potent small molecule inhibitor of Polθ, a synthetic lethality target linked to breast cancer gene (BRCA) mutations and other genomic alterations.
In May 2025, Repare entered an out-licensing agreement with Canadian biotechnology firm DCx Biotherapeutics for discovery platforms and intellectual property (IP).
